161 related articles for article (PubMed ID: 36479659)
1. Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study.
Leonhardt CS; Kinny-Köster B; Hank T; Habib JR; Shoucair S; Klaiber U; Cameron JL; Hackert T; Wolfgang CL; Büchler MW; He J; Strobel O
Ann Surg Oncol; 2023 Apr; 30(4):2433-2443. PubMed ID: 36479659
[TBL] [Abstract][Full Text] [Related]
2. Demographic, clinical, and pathological features of early onset pancreatic cancer patients.
Ntala C; Debernardi S; Feakins RM; Crnogorac-Jurcevic T
BMC Gastroenterol; 2018 Sep; 18(1):139. PubMed ID: 30208959
[TBL] [Abstract][Full Text] [Related]
3. Early-onset pancreatic cancer: a population-based study using the SEER registry.
Ansari D; Althini C; Ohlsson H; Andersson R
Langenbecks Arch Surg; 2019 Aug; 404(5):565-571. PubMed ID: 31377855
[TBL] [Abstract][Full Text] [Related]
4. Early vs conventional onset pancreatic ductal adenocarcinoma: analysis of surgical and oncologic outcomes in patients undergoing curative intent resection.
Zironda A; Zhang C; Day C; McWilliams RR; Starlinger P; Warner SG; Smoot RL; Cleary SP; Kendrick ML; Truty MJ; Thiels CA
HPB (Oxford); 2024 Jan; 26(1):145-153. PubMed ID: 37752029
[TBL] [Abstract][Full Text] [Related]
5. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Macedo FI; Ryon E; Maithel SK; Lee RM; Kooby DA; Fields RC; Hawkins WG; Williams G; Maduekwe U; Kim HJ; Ahmad SA; Patel SH; Abbott DE; Schwartz P; Weber SM; Scoggins CR; Martin RCG; Dudeja V; Franceschi D; Livingstone AS; Merchant NB
Ann Surg; 2019 Sep; 270(3):400-413. PubMed ID: 31283563
[TBL] [Abstract][Full Text] [Related]
9. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
[TBL] [Abstract][Full Text] [Related]
11. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes.
Takeda T; Sasaki T; Inoue Y; Okamoto T; Mori C; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Takahashi Y; Saiura A; Sasahira N
Pancreatology; 2022 May; 22(4):507-515. PubMed ID: 35422382
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
13. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
[TBL] [Abstract][Full Text] [Related]
14. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.
Gavazzi F; Capretti G; Giordano L; Ridolfi C; Spaggiari P; Sollai M; Carrara S; Nappo G; Bozzarelli S; Zerbi A
Dig Liver Dis; 2022 Jun; 54(6):826-833. PubMed ID: 34219044
[TBL] [Abstract][Full Text] [Related]
16. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
17. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Tumor Location on Resection and Survival for Pancreatic Ductal Adenocarcinoma.
Winer LK; Dhar VK; Wima K; Morris MC; Lee TC; Shah SA; Ahmad SA; Patel SH
J Surg Res; 2019 Jul; 239():60-66. PubMed ID: 30802706
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
20. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma.
Capretti G; Nebbia M; Gavazzi F; Nappo G; Ridolfi C; Sollai M; Spaggiari P; Bozzarelli S; Carrara S; Luberto A; Zerbi A
Pancreatology; 2022 Sep; 22(6):782-788. PubMed ID: 35701318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]